TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05034107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Approximately 6-7 drops of Ylang-ylang essential oil will be diffused in a common area estimated to be about 300 square feet with temperature of around 25 - 26 degree Celsius and humidity of 50% - 60%. Water and essential oil will be diffused twice a day, each for a duration of 20 min during the respective phases.
Study: NCT06181890

Intervention type: OTHER
Intervention: Motivational Interview
Description: The data of the research will be collected between October 2023 and June 2024. Each meeting will last approximately 15-30 minutes.
Study: NCT05287633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients are given a box of capsules of which they take 1capsule/day during the month of ramadan
Study: NCT05954247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1543
Description: DWJ1543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202216
Description: DWC202216
Study: NCT05304676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: KTT group
Description: This group will receive neurodevelopmental treatment along with kinesotape and neuromuscular electrical stimulation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: conventional treatment
Description: Group B will receive neurodevelopment treatment along with neuromuscular electrical stimulation.
Study: NCT04763954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rethink therapeutic game
Description: The Rethink therapeutic game is a 7 levels online game developed and tested for children. Each level is based on a specific skill and its efficiency has been previously studies in children.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rethink therapeutic game
Description: The Rethink therapeutic game is a 7 levels online game developed and tested for children. Each level is based on a specific skill and its efficiency has been previously studies in children.
Study: NCT06034353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist-led Cognitive Behavioral therapy
Description: Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacist-led Cognitive Behavioral therapy
Description: Pharmacist-led Cognitive Behavioral therapy is patient centered approach that focus both physical and emotional aspect of health is provided. It is focused to identify negative and change negative thought pattern and behavior to improve mental and physical well being.Incorporation education about healthy meal choices, relaxation techniques, self management strategies,to improve education about potential adverse effect, how to recognize and on followup calls how to adjust medication doses along with this is provided.
Study: NCT04628065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: #BabyLetsMove
Description: This intervention will use mobile phones to promote the adoption and maintenance of physical activity, exercise and reduced TV time among overweight or obese, Black, pregnant (\<16 weeks) adolescents (15 - 19 years) enrolled in Mississippi's WIC program.
Study: NCT05577637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily
Description: 0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily
Description: 0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily
Study: NCT05099159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080)
Description: 120 mg elinzanetant orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elinzanetant (BAY3427080)
Description: 120 mg elinzanetant orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo orally once daily
Study: NCT05188378

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P47
Description: 162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
Study: NCT06191575

Intervention type: PROCEDURE
Intervention: 7 Tesla Magnetic Resonance Imaging
Description: Undergo 7T MRI

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Intervention: Cognitive Assessment
Description: Undergo cognitive assessment
Study: NCT05188378

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved RoActemra,
Description: 162 mg in 0.9 mL, a single subcutaneous (SC) injection via pre-filled syringe (PFS)
Study: NCT05427942

Intervention type: DRUG
Intervention: Adalimumab
Description: Stable and treated for at least 3 months prior to inclusion either with an adalimumab biosimilar or originator adalimumab (40 mg dose injections only) and for whom the treating physician has decided to switch to Yuflyma® (40 mg / 0.4 mL) on the day of their inclusion (decision independent from the study)

Intervention type: DRUG
Intervention: Adalimumab
Description: Stable and treated for at least 3 months prior to inclusion either with an adalimumab biosimilar or originator adalimumab (40 mg dose injections only) and for whom the treating physician has decided to switch to Yuflyma® (40 mg / 0.4 mL) on the day of their inclusion (decision independent from the study)
Study: NCT02773082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reclaim™ DBS Therapy
Description: DBS is indicated for bilateral stimulation of the ventral anterior limb of the internal capsule as an adjunct to medications and as an alternative to anterior capsulotomy for treatment of chronic, severe, treatment-resistant obsessive compulsive disorder (OCD) in adult patients who have failed at least three selective serotonin reuptake inhibitors (SSRIs). Medtronic received humanitarian device exemption (HDE) approval for Reclaim DBS Therapy for the management of OCD on February 19, 2009.
Study: NCT04607122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Landiolol
Description: Continuous infusion of landiolol starting at 1 µg/kg/min and increasing every 10-15 minutes with incremental doses of 0.5 µg/kg/min up to 2 µg/kg/min by maintaining MAP ≥ 65 mmHg and HR ≥ 50/min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Continuous infusion of saline solution at the same rate as landiolol infusion.
Study: NCT05830877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the acupuncture group
Description: The primary choice is to puncture GB20 with a quick puncture, which means regulate the mind and open the way. ①Scalp acupuncture: Du 20(Baihui), EX-HN 3(Yintang), EX-HNl(Sishencong); ②Select acupoints from six acupoints for mind-regulating, ear points (both sides): heart, lung, and Shenmen; body points (both sides): LI20(Yingxiang), EXTRA 12(Anmian), ST36(Zusanli) as the main hole. ③Sleeping three needles(both sides): HT7(Shenmen), PC6(Neiguan), SP6(Sanyinjiao); ④Opening four gates: LI4(Hegu) , LR3(Taichong) ⑤Abdominal four needles:ST25(Tianshu), CV12(Zhongwan), CV4(Guanyuan). For body acupuncture, a 0.3 mm×40 mm needle was used to insert directly for 0.5-1.0 cun, and twisting to gain the qi; for auricular points, a 0.25 mm×40 mm needle was used for 2-3 minutes without manipulating the needle. The acupuncture points were retained for 30 min, and the treatment was performed once every other day, three times a week, and the curative effect was evaluated after 4 weeks of treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the placebo acupuncture group
Description: Subjects in the placebo acupuncture group will receive non-insertive acupuncture using the sham needle supported by the Park device. This needle has a retractable shaft and a blunt tip, they could not penetrate the skin. We gently placed the sham needle and Park device on the skin. The sham needle is then no longer manipulated to minimize any physiological effects. The selected acupoints and needle retention time were the same as for the acupuncture group. Since oblique insertion is required for acupuncture points on the head, the fixed acupuncture body of the Park device could not be used. Therefore, blunt needles are used to stimulate the head points to reduce the amount of stimulation produced by acupuncture. At the end of the treatment, the acupuncturist also used a dry cotton swab to press the acupoints so that patients could feel the withdrawal of 'real' needles.
Study: NCT05883618

Intervention type: OTHER
Intervention: Exposure
Description: Human Development Index of Country
Study: NCT05936515

Intervention type: OTHER
Intervention: Training of nurses and nursing assistants
Description: Training of nurses and nursing assistants, based on the model of hygiene correspondents, in order to disseminate good geriatric practices
Study: NCT05232357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate and Methylene blue solution
Description: Take a methylene blue injection (2ml:20mg), add 18ml distilled water and mix well. Add NaS2O3.5H2O800mg to the methylene blue solution 10ml, add 4 drops of dilute hydrochloric acid, heat the water bath until the dark blue fades, the solution is milky and turbid, adjust the PH to about 3.5. Put the prepared solution into a glass bottle with a rubber stopper, which is wrapped in tin foil, sealed and protected from light, and stored in a refrigerator at-20 ℃. It can be used after high-pressure sterilization before operation. Sodium thiosulfate-Methylene blue (DMB) staining solution was used as nerve staining agent. During gastroenteroscopy, DMB staining solution was locally sprayed on the surface of gastrointestinal lesion mucosa or injected into the lesion mucosa.
Study: NCT06313268

Intervention type: DRUG
Intervention: Bevacizumab Biosimilar MB02
Description: 5 mg/kg to 15 mg/kg in combination with chemotherapy.
Study: NCT05054751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB491+ Fulvestrant
Description: GB491: The dose of GB491 is 150 mg, BID, which should be taken with a meal. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles. Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.
Study: NCT06362122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: identification anatomo-clinico-biological profiles
Description: to determine an anatomo-clinico-biological correlation associating the anatomopathological profile, the clinical characteristics and the cytokine signature
Study: NCT05200689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT)
Description: Kinesio taping will only be applied for a period of 5 days. Initial Kinesio taping will first occur one day after surgery.~It will be placed directly on the chest wall on a trigger point. Physiotherapists will be instructed to maintain a standard Tape length (To body size ratio) and tension among all patients of all KT groups. The edges of the tape must be rounded, to prevent premature peeling. The adhesive side of the tape must not be touched after removing its backing, to prevent any decrease in tape adherence. It will be applied using both I and Star applications. Star and I KT application is done directly above the main pain trigger point. This point is found via chest palpitations. The Tape will be replaced every 48 hours by the physiotherapist until the end of therapy. The tape must be placed after stretching the skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT)
Description: Kinesio taping will only be applied for a period of 5 days. Initial Kinesio taping will first occur one day after surgery.~It will be placed directly on the chest wall on a trigger point. Physiotherapists will be instructed to maintain a standard Tape length (To body size ratio) and tension among all patients of all KT groups. The edges of the tape must be rounded, to prevent premature peeling. The adhesive side of the tape must not be touched after removing its backing, to prevent any decrease in tape adherence. It will be applied using both I and Star applications. Star and I KT application is done directly above the main pain trigger point. This point is found via chest palpitations. The Tape will be replaced every 48 hours by the physiotherapist until the end of therapy. The tape must be placed after stretching the skin.
Study: NCT06372184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Washed Microbiota Transplantation
Description: Patients take four capsules containing washed microbiota once a day for five consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients take four capsules in the same packaging as the experimental group once a day for five consecutive days
Study: NCT04469348

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: nasal swab
Description: nasal swab will be performed to analysis biological markers at every visit.
Study: NCT05490108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZR202-CoV
Description: SARS-CoV-2 adjuvanted recombinant protein vaccine (prototype)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZR202a-CoV
Description: SARS-CoV-2 adjuvanted recombinant protein vaccine (variant)
Study: NCT05054751

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+Fulvestrant
Description: Placebo: The dose of Placebo is 150 mg, BID, which should be taken with a meal. The placebo is administered according to the patient's dose group until the progression of disease occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.~Fulvestrant: Intramuscular injection of flurvexine 500mg on day 1 and day 15 of the first cycle, and flurvexine 500mg on day 1 of the second and subsequent cycles. Flurvexine 500mg should be given slowly (1-2 minutes per injection) on both sides of the buttocks, once 250 mg on each side. The drug is administered according to the patient's dose group until the progression of disease or an intolerable toxicity occur or meet the criteria for termination of treatment or the patient withdraw informed consent or the sponsor discontinues the trial.
Study: NCT05207397

Intervention type: OTHER
Intervention: Lactate infusion
Description: The unlabeled lactate infusion cocktail (30% L(+)-lactic acid solution (Sigma) with 2N NaOH, pH4.8) and stable isotope infusions will be made by the O'Brien Pharmacy (Mission, Kansas) and tested to be sterile and pyrogen free.. Upon arriving to the KU Clinical and Translational Science Unit, a catheter will be placed in the subject's hand, which will be placed into a heated hand box for collection of arterialized blood. A second catheter will be placed in the opposing forearm vein for the infusion of lactate isotope solution and unlabeled lactate infusion cocktail. After insertion of the catheters, and prior to isotope infusion, a background blood and breath sample (ParvoMedics TrueOne 2400) will be obtained. We will then administer priming doses of 57.5 mg \[3-13C\]lactate, 250 mg D2-glucose and 136 mg H13CO3- followed by continuous infusions of \[3-13C\]lactate at 10 mg/min and D2-glucose at 2 mg/min \[53\]. Along with the continuous isotope infusion we will begin infusion of the Na-lact
Study: NCT05490108

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comirnaty®
Description: Comirnaty® (Pfizer-BioNTech)
Study: NCT05985096

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Virtual reality group
Description: Participants in this group will be expected to meet their physical activity levels using the Oculus Quest 2 VR Goggles platform with Racket, Climb, Acron, Skiing, Cycling games.
Study: NCT06000605

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fed
Description: Participants will eat a light meal prior to testing and be fed a light meal during testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasted
Description: Participants will completely abstain from calories for 72 hours prior to testing and not receive any calories during testing.
Study: NCT05569694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement-based pelvic health education
Description: A single virtual education session led by a physical therapist trained in pelvic health. The virtual course was approximately one hour and included movement-based education through various positions, exercises, and movements with explanations for each pose as it relates to pelvic health.
Study: NCT05659628

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CD19-7×19 CAR-T combined with Tislelizumab
Description: Participants will receive 2×106/Kg CD19-7×19 CAR-T cells infusion and Tislelizumab 200mg every 21 days for 6 cycle on the 31st day after CAR-T infusion.
Study: NCT04713826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116
Description: 160 µg, nasal spray administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2586116
Description: 160 µg, nasal spray administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BAY2586116, nasal spray administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BAY2586116, nasal spray administration.
Study: NCT04894396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aetrex L2305 Premium Memory Foam Orthotics W/ Metatarsal Support
Description: An Orthotic insole to be inserted into shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia. For medium to high arches with forefoot pain, featuring a cupped heel to cushion and stabilize the back of foot and a metatarsal pad to redistribute weight to relieve ball-of-foot discomfort. With 43% more memory foam in the forefoot for those experiencing foot discomfort or fatigue.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aetrex L2300 Premium Memory Foam Orthotics
Description: An Orthotic insole to be inserted into shoes. Features Aetrex Arch Support to help biomechanically align the body \& help prevent common foot pain such as Plantar Fasciitis, Arch Pain and Metatarsalgia. With 43% more memory foam in the forefoot for those experiencing foot discomfort or fatigue.
Study: NCT05524181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth Integrated Primary Care (TIPC)
Description: The TIPC model of intervention incorporates video visits across research clinicians and patients' existing care clinicians for more synergized and accessible care provision for a given clinical indication. The first TIPC visit will center around the patient setting care goals for themselves and their caregiver with the help of a palliative care physician. The second TIPC visit will focus on assessing goal attainment and also close the care loop between their existing care team, a research-appointed palliative care team, and their involvement in the study.
Study: NCT06127459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental Guidance
Description: Parents get guidance for children's positive behaviour support by using parts of Self-Help Program on the MentalHub.fi (in Finnish: Mielenterveystalo.fi) website regarding children's challenging behaviour (in Finnish: Lasten haastavan käytöksen omahoito-ohjelma).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Game
Description: Virtual reality game for rehabilitation of attention, activity control and executive functions by using the virtual environment that corresponds to the typical everyday situations at home.
Study: NCT06301191

Intervention type: DRUG
Intervention: Semaglutide, 1.0 mg/mL
Description: Semaglutide, 1.0 mg/mL

Intervention type: DRUG
Intervention: Dipeptidyl Peptidase 4 inhibitor
Description: Dipeptidyl Peptidase 4 inhibitor
Study: NCT06582186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualization of first voriconazole maintenance doses
Description: Individualization of first voriconazole maintenance doses
Study: NCT04449211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: Reconstructing the long bone defect with 3D-printed customised Titanium alloy implant
Study: NCT05320887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Nicotine Content Vape with all flavor e-liquids
Description: Participants are randomly assigned to the order of each marketplace Group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal nicotine content vape with tobacco e-liquids
Description: Participants are randomly assigned to the order of each marketplace Group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low nicotine content vape with all flavor e-liquids
Description: Participants are randomly assigned to the order of each marketplace Group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low nicotine content vape with tobacco e-liquids
Description: Participants are randomly assigned to the order of each marketplace Group
Study: NCT05235516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: q3w iv

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: EBRT
Description: 45-50.4Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: EBRT
Description: 45-50.4Gy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: BT
Description: ≥80Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: BT
Description: ≥80Gy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: qw iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: qw iv

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: q3w iv